Previous 10 | Next 10 |
2024-01-05 16:10:58 ET More on PMV Pharmaceuticals PMV Pharmaceuticals: In A Stronger Position Now Than Before, At A Lower Price Ladenburg Thalmann starts PMV Pharmaceuticals at buy For further details see: PMV Pharmaceuticals names Michael Carulli as CFO
PC14586 clinical program to be led by Deepika Jalota, Pharm.D. (Chief Development Officer) and Marc Fellous, M.D. (Senior Vice President, Head of Clinical Development and Medical Affairs) Michael Carulli promoted to Chief Financial Officer Robert Ticktin, General Counsel, will exp...
2023-12-28 16:12:39 ET More on PMV Pharmaceuticals PMV Pharmaceuticals: In A Stronger Position Now Than Before, At A Lower Price Seeking Alpha’s Quant Rating on PMV Pharmaceuticals Historical earnings data for PMV Pharmaceuticals Financial information ...
2023-11-14 18:50:05 ET Summary PMV Pharmaceuticals' phase 1/2 trial of its drug, PC14586, in solid tumors with a Y220C p53 mutation produced initial data in 2022, but the response was mixed. A 2023 update on data from the phase 1/2 trial is a net positive, in my opinion, with conf...
PMV Pharmaceuticals Inc. (PMVP) is expected to report $-0.45 for Q3 2023
2023-11-09 13:22:55 ET More on PMV Pharmaceuticals PMV Pharmaceuticals: A 5-Month Run-Up Is Justified Seeking Alpha’s Quant Rating on PMV Pharmaceuticals Historical earnings data for PMV Pharmaceuticals Financial information for PMV Pharmaceuticals ...
Updated data from Phase 1 PYNNACLE clinical trial of PC14586 presented at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics demonstrated responses across multiple tumor types with median duration of response of seven months An overall response rate ...
2023-10-12 13:26:41 ET More on Femasys, Jaguar Health, etc. Jaguar Health, Inc. (JAGX) Q2 2023 Earnings Call Transcript LogicMark, Inc. (LGMK) Q2 2023 Earnings Call Transcript Femasys regains Nasdaq compliance Jaguar Health's Napo Pharma gets patent in Japan ...
Updated PC14586 Phase 1 data presented today as a late-breaking poster at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Confirmed responses observed in multiple tumor types including ovarian, breast, prostate, lung, and endometrial cancer with m...
PRINCETON, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that it will present updated Phase 1 data from the ong...
News, Short Squeeze, Breakout and More Instantly...
PMV Pharmaceuticals Inc. Company Name:
PMVP Stock Symbol:
NASDAQ Market:
2024-05-13 08:30:02 ET Craig-Hallum analyst issues BUY recommendation for PMVP on May 13, 2024 07:30AM ET. PMVP was trading at $2.04 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 3 - Buy recommendations...
First patient dosed and continued enrollment in Phase 2 portion of the PYNNACLE trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumors Phase 1 data of rezatapopt in advanced ovarian cancer featured in late-breaking ora...